This document shares up-to-date, community-preferred terminology within cure research.
Language for HIV Cure
A Comprehensive Approach for Progress
Ending the Epidemic
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
The Case For an HIV Cure and How to Get There
Viewpoint appearing in The Lancet HIV
Appearing in The Lancet HIV: We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
What’s All the Buzz About: mRNA, manufacturing, vaccine access
Exploring the potential role of bNAbs in prevention
AVAC and partners hosted a conversation to explore the potential role of bNAbs in prevention, current status in the field, and key issues to consider in HIV vaccine research.
Panelists included: Slim Karim, CAPRISA, Pervin Anklesaria, Bill & Melinda Gates Foundation, Khadija Richards, Wits RHI, Huub Gelderblom, HIV Vaccine Trials Network (HVTN)
Hosted By: Mitchell Warren, AVAC and Stacey Hannah, AVAC
Recording / Slim Karim Slides / Pervin Anklesaria Slides / Khadija Richards Slides / Huub Gelderblom Slides
AVAC Partnership Strategy 2023-2026
This document lays out AVAC’s plan to transition away from traditional power structures when working with partners — from civil society advocates to scientists, policy makers, program implementers, and more. AVAC strives towards a model in which those with lived experience and field expertise have influence and equal voice in the design and delivery of plans and priorities.
Experimental Medicine Vaccine Trials (EMVTs): Opportunities and Challenges
In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.
Including Pregnant and Breastfeeding People in Trials of Novel LAED PrEP Agents
Perspective from sub-Saharan Africa community stakeholders
This paper describes how community consultation based in the principles of GPP led to researchers gaining an enhanced understanding of their community’s strongly held views and concerns about PrEP for pregnant and lactating people, and whether and how to include of those people in PrEP research.
hivresourcetracking.org
The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.
In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.
Much Accomplished, Much to Do: A Conversation Looking Back & Looking Ahead with Tony Fauci
November 28, 2022
AVAC Executive Director Mitchell Warren spoke with NIAID Director, Anthony Fauci to discuss all that’s been accomplished in the HIV and COVID-19 responses over the years, what’s ahead, and what the future looks like for NIAID, for Dr. Fauci and for pandemic preparedness.